Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615544 | 0.90 | ALDH1A1 (0.53) | EPHX1ALDH1A1TP53KDM4EGMNN | |
| SCHEMBL16281688 | 0.89 | ALDH1A1 (0.44) | EPHX1ALDH1A1TP53KDM4EGMNN | |
| SCHEMBL11519202 | 0.87 | ALDH1A1 (0.50) | EPHX1ALDH1A1TP53KDM4EGMNN | |
| SCHEMBL29007633 | 0.87 | EPHX1 (0.40) | EPHX1ALDH1A1TP53KDM4EGMNN | |
| SCHEMBL13767350 | 0.86 | SHBG (0.48) | EPHX1ALDH1A1TP53KDM4EGMNN | |
| SCHEMBL10659158 | 0.82 | DNM1 (0.37) | EPHX1ALDH1A1SHBGMEN1KMT2A | |
| SCHEMBL18924690 | 0.82 | DNM1 (0.37) | EPHX1ALDH1A1SHBGMEN1KMT2A | |
| SCHEMBL11515656 | 0.82 | ALDH1A1 (0.45) | EPHX1ALDH1A1TP53KDM4EGMNN | |
| SCHEMBL3429556 | 0.81 | EPHX1 (0.39) | EPHX1ALDH1A1TP53KDM4EGMNN | |
| SCHEMBL2067551 | 0.79 | EPHX1 (0.64) | EPHX1ALDH1A1TP53KDM4EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288640-B1 | WATER SOLUBLE AMINE AND ITS APPLICATION | SIKA TECH AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-9290603-B2 | Amines having secondary aliphatic amino groups | SIKA TECHNOLOGY AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-20130237681-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECHNOLOGY AG (CH) | 2013-09-12 | — | — | US | disclosed |
| EP-2288640-A1 | WATER-SOLUBLE AMINE AND USES THEREOF | Sika Technology AG (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150212-A1 | WATER-SOLUBLE AMINE AND USES THEREOF | SIKA TECHNOLOGY AG (CH) | 2009-12-17 | — | — | WO | disclosed |
| EP-2132246-A1 | METHOD FOR THE PRODUCTION OF POLYURETHANE COMPOSITIONS WITH A LOW ISOCYANATE MONOMER CONTENT | Sika Technology AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116927-A1 | METHOD FOR THE PRODUCTION OF POLYURETHANE COMPOSITIONS WITH A LOW ISOCYANATE MONOMER CONTENT | SIKA TECHNOLOGY AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| EP-1975187-A1 | Method for manufacturing polyurethane compounds with low isocyanate-monomer content | Sika Technology AG (CH) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237681-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | AAAS, PNMT, PARG | EPHX1 405/4885ALDH1A1 1074/4885TP53 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.